These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9103514)

  • 1. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.
    Caraco Y; Sheller J; Wood AJ
    J Pharmacol Exp Ther; 1997 Apr; 281(1):330-6. PubMed ID: 9103514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
    Caraco Y; Sheller J; Wood AJ
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.
    Caraco Y; Sheller J; Wood AJ
    J Pharmacol Exp Ther; 1999 Jul; 290(1):413-22. PubMed ID: 10381807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.
    Lötsch J; Skarke C; Schmidt H; Rohrbacher M; Hofmann U; Schwab M; Geisslinger G
    Clin Pharmacol Ther; 2006 Jan; 79(1):35-48. PubMed ID: 16413240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
    Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
    Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 phenotype-specific codeine population pharmacokinetics.
    Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
    J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
    Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
    Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacogenetics of codeine hypoalgesia.
    Sindrup SH; Brøsen K
    Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine.
    Hasselström J; Yue QY; Säwe J
    Eur J Clin Pharmacol; 1997; 53(2):145-8. PubMed ID: 9403287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
    Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
    Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.
    Yue QY; Hasselström J; Svensson JO; Säwe J
    Br J Clin Pharmacol; 1991 Jun; 31(6):635-42. PubMed ID: 1867957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
    Dilger K; Hofmann U; Klotz U
    Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
    Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK
    Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the assessment of drug metabolism by assays of codeine and its main metabolites.
    Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
    Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
    Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
    Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
    Thompson CM; Wojno H; Greiner E; May EL; Rice KC; Selley DE
    J Pharmacol Exp Ther; 2004 Feb; 308(2):547-54. PubMed ID: 14600248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.